{
    "pmcid": "8967979",
    "qa_pairs": {
        "How was the nanobody Nb22 initially isolated for use against SARS-CoV-2?": [
            "From an alpaca immunized with the SARS-CoV-2 spike protein",
            "From a llama immunized with the SARS-CoV-2 nucleocapsid protein",
            "From a camel immunized with the SARS-CoV-2 membrane protein",
            "From a dromedary immunized with the SARS-CoV-2 envelope protein"
        ],
        "What is a key advantage of nanobodies like Nb22 in terms of production and storage?": [
            "They can be produced at low cost in prokaryotic systems and are suitable for non-cold chain storage",
            "They require complex eukaryotic systems for production and must be stored at low temperatures",
            "They are expensive to produce and require cold chain storage",
            "They can only be produced in mammalian cell cultures and need refrigeration"
        ],
        "What is the method of administration for Nb22 that provided complete protection in hACE2 transgenic mice?": [
            "Intranasal administration",
            "Intravenous administration",
            "Oral administration",
            "Subcutaneous administration"
        ],
        "What is the primary target of the nanobody Nb22 in the SARS-CoV-2 virus?": [
            "The receptor-binding domain (RBD) of the spike protein",
            "The nucleocapsid protein",
            "The membrane protein",
            "The envelope protein"
        ],
        "What specific mutation in the Delta variant enhances the binding affinity of Nb22?": [
            "L452R",
            "D614G",
            "N501Y",
            "E484K"
        ]
    }
}